Infant and children formula for early intervention to enhance memory capacity in adulthood of individuals and preparation method and use thereof

Abstract

The present application provides an infant and child formula for early intervention to improve the memory ability of individuals in adulthood and a preparation method and use thereof. Specifically, the present application provides the use of human milk oligosaccharides as active components in the preparation of an infant or child formula for helping to improve and / or improve the memory ability of individuals in adulthood, wherein the human milk oligosaccharides are selected from one or more of 2'-fucosyllactose (2'-FL), 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), and the total protein content is 10-30 g / 100 g, the fat content is 10-35 g / 100 g, the carbohydrate content is 45-65 g / 100 g, and the dietary fiber content is 0-6.5 g / 100 g based on the dry matter of the infant or child formula. The infant and child formula of the present application can help improve the memory in adulthood.

Description

Technical Field

[0001] This invention relates to the field of infant and child food technology, specifically to an infant and child formula food, its preparation method, and its uses. Background Technology

[0002] Human milk oligosaccharides (HMOs), the third largest solid substance in breast milk after lactose and fat, play a vital role in the healthy growth and development of infants, especially in their neural, brain, and cognitive development. Currently, the structures of over 200 HMOs have been identified. Each HMO molecule contains 3-14 monosaccharides linked in a straight or branched chain. Based on their monosaccharide composition, HMOs can be classified into three main categories: fucoidylated human milk oligosaccharides, sialylated human milk oligosaccharides, and neutral human milk oligosaccharides. Significant progress has been made in research on the impact of HMOs on cognitive development over the past two decades. Although clinical trials in human infants present challenges, animal studies consistently demonstrate that HMOs are beneficial for neural development, neurogenesis, neural circuit formation, and memory function.

[0003] 2'-FL, short for 2'-fucosylated lactose, can effectively regulate the balance of intestinal flora, promote the growth of beneficial bacteria such as Bifidobacteria, thereby maintaining intestinal health and enhancing immunity. Studies have also shown that this component has a positive promoting effect on brain development and cognitive function, and can improve memory and learning ability, which is especially important in the growth and development stage of infants and young children.

[0004] 3'-SL, short for 3'-sialic acid lactose sodium salt, excels in supporting infant brain development. Numerous studies have confirmed its crucial support for synapse formation and cognitive enhancement, making it a core component for precisely mimicking breast milk nutrition. It is also a high-quality prebiotic, effectively regulating gut microbiota balance, promoting the colonization and growth of beneficial bacteria such as Bifidobacteria, thereby maintaining gut health and building a healthy gut microbiota barrier. Furthermore, it exerts its anti-infective function by acting as a decoy receptor to prevent pathogens from attaching to intestinal epithelial cells. In addition, this component exhibits significant anti-inflammatory activity, maintaining immune homeostasis and showing potential in the prevention and treatment of osteoarthritis by promoting cartilage formation and inhibiting cartilage tissue destruction.

[0005] 6'-SL, short for 6'-sialic acid lactose sodium salt, has shown significant efficacy in promoting infant neurodevelopment and improving motor function. Clinical studies have also confirmed that the content of 6'-sialic acid lactose in breast milk is positively correlated with the cognitive development index of infants. It can synergistically promote infant cognitive development and learning ability by forming key active molecules for neurodevelopment such as gangliosides and polysialic acid-neuronal cell adhesion molecules, and by regulating the gut microbiota to produce short-chain fatty acids and neuroactive metabolites through the brain-gut axis. At the same time, as a prebiotic, it can also promote the colonization of beneficial bacteria such as Bifidobacteria, inhibit pathogen adhesion, and improve gut health.

[0006] In the field of infant and toddler formula, a core technical challenge is how to design and prepare formulas that can mimic the nutritional components and functions of breast milk to promote the healthy growth of infants and toddlers. Breast milk not only provides essential nutrients but also contains a variety of bioactive components that have a significant impact on the neurodevelopment and behavioral performance of infants and toddlers. However, when breast milk is scarce or insufficient, existing infant and toddler formulas often fail to fully replicate these complex components and functions of breast milk, especially in promoting social and behavioral development.

[0007] Research has revealed few existing studies on the impact of diet on adult memory. Summary of the Invention

[0008] The inventors in this case discovered in their research that intervening in human milk oligosaccharides in early life can have a positive effect on cognitive development in adulthood, especially memory ability.

[0009] Furthermore, one objective of this invention is to provide an infant or child formula food that enhances an individual's memory ability in adulthood through early intervention, thereby assisting in memory improvement.

[0010] Another object of the present invention is to provide a method for preparing the infant or child formula food.

[0011] Another object of the present invention is to provide the use of the said infant or child formula food.

[0012] On the one hand, the present invention provides an infant or child formula food that helps to enhance and / or improve an individual's memory ability in adulthood, wherein, based on the dry matter content of the infant or child formula food, the total protein content is 10g-30g / 100g, the fat content is 10g-35g / 100g, the carbohydrate content is 45g-65g / 100g, and the dietary fiber content is 0-6.5g / 100g; The human milk oligosaccharide is selected from one or more of 2'-fucosylated lactose (2'-FL or 2-FL), 3'-sialylated lactose (3'-SL), and 6'-sialylated lactose (6'-SL).

[0013] On the other hand, the present invention also provides the use of human milk oligosaccharides as an active ingredient in the preparation of infant or child formula foods that help enhance and / or improve an individual's memory ability in adulthood; The total protein content of the infant or child formula food, calculated by dry matter, is 10g-30g / 100g, the fat content is 10g-35g / 100g, the carbohydrate content is 45g-65g / 100g, and the dietary fiber content is 0-6.5g / 100g. The human milk oligosaccharide is selected from one or more of 2'-fucosylated lactose (2'-FL), 3'-sialylated lactose (3'-SL), and 6'-sialylated lactose (6'-SL); The product is an oral product intended for use by minors.

[0014] According to some specific embodiments of the present invention, in the infant or child formula of the present invention, the human milk oligosaccharide is: 2'-Fucose-based lactose; 3'-Sialolactose; 6'-Sialolactose; A combination of 3'-sialyl lactose and 6'-sialyl lactose; or A combination of 2'-fucosylated lactose, 3'-sialylated lactose and 6'-sialylated lactose.

[0015] According to some specific embodiments of the present invention, in the infant or child formula food of the present invention, the mass ratio of 3'-sialic acid lactose to 6'-sialic acid lactose in the combination of 3'-sialic acid lactose to 6'-sialic acid lactose is 1:(1-4), preferably 1:(1.5-2.5) or 1:(2-3).

[0016] According to some specific embodiments of the present invention, in the infant or child formula food of the present invention, in the combination of 2'-fucosylated lactose, 3'-sialic acid lactose and 6'-sialic acid lactose, the mass ratio of 2'-fucosylated lactose, 3'-sialic acid lactose and 6'-sialic acid lactose is (1-12):1:(1-4), preferably (1-12):1:(2-3) or (1-12):1:(1.5-2.5), and more preferably (4-10):1:(2-3).

[0017] According to some specific embodiments of the present invention, the total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL in the infant or child formula of the present invention, based on the dry matter of the infant or child formula, is 10-6000 mg / 100g of dry matter.

[0018] According to some specific embodiments of the present invention, the total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL in the infant or child formula of the present invention is 10-4000 mg / 100g of dry matter.

[0019] According to some specific embodiments of the present invention, the total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL in the infant or child formula of the present invention is 20-2387 mg / 100g of dry matter.

[0020] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 20-1900 mg / 100g of dry matter.

[0021] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 20-1800 mg / 100g of dry matter.

[0022] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 50-1700 mg / 100g of dry matter.

[0023] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 100-1600 mg / 100g of dry matter.

[0024] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 200-1500 mg / 100g of dry matter.

[0025] According to some specific embodiments of the present invention, the amount of human milk oligosaccharides contained in the infant or child formula of the present invention is 400-1200 mg / 100g of dry matter.

[0026] According to some specific embodiments of the present invention, in the infant or child formula of the present invention, when the human milk oligosaccharide contains 3'-sialic acid lactose, the amount of 3'-sialic acid lactose in the food is usually 10-400 mg / 100g of dry matter.

[0027] According to some specific embodiments of the present invention, in the infant or child formula of the present invention, when the human milk oligosaccharide contains 6'-sialic acid lactose, the amount of 6'-sialic acid lactose in the food is generally 5-800 mg / 100g of dry matter. For example, the amount of 6'-sialic acid lactose in the food can be 5-50 mg / 100g of dry matter, 50-100 mg / 100g of dry matter, 100-200 mg / 100g of dry matter, 200-500 mg / 100g of dry matter, or 500-800 mg / 100g of dry matter.

[0028] It is understandable that, for different types of food, the content of each human milk oligosaccharide in the final product should be appropriately adjusted within the range allowed by relevant standards and regulations.

[0029] According to some specific embodiments of the present invention, the infant or child formula foods of the present invention include, but are not limited to: powdered infant formula foods, liquid infant formula foods, powdered modified infant milk powder, special medical purpose infant formula foods, cheese, and milk tablets, wherein the powdered infant formula foods include powdered infant formula foods, powdered follow-up formula foods, or powdered toddler formula foods, and the liquid infant formula foods include liquid infant formula foods, liquid follow-up formula foods, or liquid toddler formula foods.

[0030] According to a specific embodiment of the present invention, the raw materials providing total protein in the infant and child formula foods of the present invention include one or more of the following: raw milk (cow / sheep), whole milk powder (cow / sheep), skim milk powder (cow / sheep), skim milk (cow / sheep), whey protein powder (cow / sheep), hydrolyzed whey protein powder (cow / sheep), demineralized whey powder / liquid (cow / sheep), β-casein, etc.

[0031] According to a specific embodiment of the present invention, the raw materials for providing fat in the infant and child formula foods of the present invention include not only the basic raw material of milk fat, but also vegetable oil or OPO structured lipids.

[0032] According to a specific embodiment of the present invention, the raw materials providing carbohydrates in the infant and child formula foods of the present invention include: 0-350 parts of lactose, and / or the above-mentioned protein raw materials containing lactose.

[0033] According to a specific embodiment of the present invention, in the infant and child formula of the present invention, a portion of the carbohydrates are derived from lactose-containing base ingredients such as milk, whole milk powder, and / or skim milk powder, and additional lactose is added to provide carbohydrates. That is, in the infant and child formula of the present invention, the carbohydrate-providing ingredients include lactose in addition to the lactose-containing base ingredients. Preferably, based on 1000 parts by weight of the infant and child formula, the ingredients include: 0-330 parts by weight of lactose. The specific amount of lactose added can be adjusted within the above range so that the carbohydrate content of the infant and child formula of the present invention is 45-60g / 100g.

[0034] According to a specific embodiment of the present invention, the raw materials of the infant and child formula of the present invention may further include one or more combinations of appropriate nucleotides, lactoferrin, lutein, etc. Preferably, based on 1000 parts by weight of the infant and child formula of the present invention, the raw materials include: 0-1 parts by weight of nucleotides and 0-8.5 parts by weight of lactoferrin.

[0035] According to a specific embodiment of the present invention, the raw materials of the infant and child formula of the present invention may further include a compound nutrient containing calcium powder, vitamins, and minerals. This compound nutrient is a combination of nutritional components that meet national standards, and different amounts are added according to different formulas. Preferably, based on 1000 parts by weight of infant and child formula, the raw materials include: 4.5-37.5 parts by weight of a compound nutrient containing calcium powder, vitamins, and minerals. More preferably, the compound nutrient is added at least in the form of a compound vitamin packet, calcium powder, and mineral nutrient packet.

[0036] Specifically, the compound nutrients are preferably added in the form of the following nutrient packets: 1) The content of each component in the compound vitamin nutritional pack is as follows: Taurine: 0-340mg Vitamin A: 1200-7000 μgRE Vitamin D: 20-112 μg Vitamin B1: 1500-14000μg Vitamin B2: 3500-14000 μg Vitamin B6: 1000-7000μg Vitamin B 12 8-30μg Vitamin K1: 200-750 μg Vitamin C: 0-800mg Vitamin E: 10-70mg α-TE Nicotinamide: 10000-47000μg Folic acid: 420-3000μg Biotin: 38-245μg Pantothenic acid: 6000-60000μg Inositol: 0-250mg L-carnitine: 0-150mg 2) Mineral 2 Nutrition Pack: The content of each component per gram of the Mineral 2 Nutrition Pack is as follows: Calcium: 120-6000mg Phosphorus: 0-150mg 3) Mineral and Nutritional Pack: The content of each component in each gram of the Mineral and Nutritional Pack is as follows: Iron: 25-135mg Zinc: 23-175mg Copper: 2600-12000μg Iodine: 0-995μg Selenium: 0-200μg Manganese: 0-15000μg 4) Compound magnesium chloride nutritional supplement, each gram of compound magnesium chloride nutritional supplement contains: Magnesium: 80-2800mg 5) Compound potassium chloride nutrient pack, each gram of compound potassium chloride nutrient pack contains: Potassium: 0-580mg; 6) Choline chloride nutritional supplement, each gram of choline chloride nutritional supplement contains: Choline: 300-1500mg; Preferably, based on 1000 parts by weight of infant and child formula, the amount of the compound vitamin nutrient pack added is 2-5 parts by weight, the amount of the mineral II nutrient pack added is 2-20 parts by weight, the amount of the mineral I nutrient pack added is 0.5-3 parts by weight, the amount of the compound magnesium chloride nutrient pack added is 0-2 parts by weight, the amount of the compound potassium chloride nutrient pack added is 0-4.5 parts by weight, and the amount of choline chloride nutrient pack added is 0-3 parts by weight. The base material of each nutrient pack is preferably lactose, maltodextrin, or sodium L-ascorbate.

[0037] In an infant formula of the present invention, the phospholipids and / or anhydrous butter used are mainly for the formation of powder particles during the spray drying process. The phospholipids can be soybean phospholipids and / or lecithin. Although the amount of phospholipids and anhydrous butter used is relatively small, they still contribute to the fat content of the milk powder product.

[0038] According to some specific embodiments of the present invention, the infant or child formula food of the present invention, wherein, based on the preparation of 1000 parts by weight of the powdered infant formula food, the raw material composition of the powdered infant formula food includes: 0-7000 parts by weight of raw milk, 0-600 parts by weight of demineralized whey powder, 0-500 parts by weight of lactose, 0-600 parts by weight of skim milk powder, 0-400 parts by weight of edible vegetable blended oil, 0-250 parts by weight of dietary fiber, 0-170 parts by weight of whey protein powder, 0-20 parts by weight of phospholipids, 0-20 parts by weight of vitamins, 0-40 parts by weight of casein, and 0-30 parts by weight of minerals; To prepare 1000 parts by weight of the aforementioned infant formula liquid milk, the raw material composition of the infant formula liquid milk includes: 0-930 parts by weight of water, 0-950 parts by weight of raw milk, 0-75 parts by weight of skim milk powder, 0-75 parts by weight of demineralized whey powder, 0-75 parts by weight of lactose, 0-60 parts by weight of edible vegetable blended oil, 0-35 parts by weight of dietary fiber, 0-18 parts by weight of whey protein powder, 0-2 parts by weight of phospholipids, 0-6 parts by weight of casein, 0-3 parts by weight of vitamins, and 0-5 parts by weight of minerals; Based on the preparation of 1000 parts by weight of the powdered infant formula milk powder, the raw material composition of the powdered infant formula milk powder includes 0-7000 parts by weight of raw milk, 0-500 parts by weight of skim milk powder, 0-300 parts by weight of demineralized whey powder, 0-170 parts by weight of whey protein powder, 0-500 parts by weight of lactose, 0-250 parts by weight of dietary fiber, 0-5 parts by weight of choline, 0-10 parts by weight of phospholipids, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals.

[0039] According to some specific embodiments of the present invention, the raw material composition of the infant or child formula food of the present invention includes (based on the preparation of 1000 parts by weight of powdered food): 0-5200 parts by weight of raw milk; Lactose 0-330 parts by weight; Whole milk powder 0-300 parts by weight; Skim milk powder 0-500 parts by weight; Demineralized whey powder 0-580 parts by weight; Desalted whey solution, 0-4000 parts by weight; Skim milk 0-4000 parts by weight; Whey protein powder 0-170 parts by weight; 0-350 parts by weight of whey protein solution; Blended oil 0-280 parts by weight; Sunflower seed oil 0-110 parts by weight; Corn oil 0-40 parts by weight; Soybean oil 0-80 parts by weight; Coconut oil 0-30 parts by weight; Low-erucic acid rapeseed oil, 0-85 parts by weight; 0-20 parts by weight of flaxseed oil; 0-240 parts by weight of 1,3-dioleoyl-2-palmitoylglycerol triglyceride; α-lactalbumin powder 0-55 parts by weight; Whey protein powder (rich in milk fat globule membrane) 0-50 parts by weight; 0-40 parts by weight of β-casein powder; 0-5 parts by weight of soybean lecithin; 0-2 parts by weight of anhydrous butter; 0-50 parts by weight of fructooligosaccharide powder; 0-100 parts by weight of galactooligosaccharide syrup; A complex of nutrients containing calcium powder, vitamins and minerals, 4.5-37.5 servings by weight; DHA 0-20 parts by weight; ARA 0-25 parts by weight; Lactoferrin 0-8.5 parts by weight; 0-1 parts by weight of nucleotides; Probiotics 0-10 parts by weight.

[0040] Note: 0-280 parts of blended oil, wherein the blended oil is selected from one or more of sunflower oil, corn oil, soybean oil, coconut oil, low erucic acid rapeseed oil, flaxseed oil, 1,3-dioleoyl-2-palmitoylglycerol, etc.

[0041] It is understood that the specific dosage of each ingredient in the infant and child formula foods of this invention should be determined by adjustment while meeting the product indicator requirements. In the infant and child formula foods of this invention, product performance indicators not detailed or listed should be implemented in accordance with the provisions of national standards and relevant standards and regulations for infant and child formula foods.

[0042] In the infant formula of this invention, all raw materials are commercially available, and the selection of each raw material should meet the relevant standards. The human milk oligosaccharides mentioned therein should also meet the requirements described in this invention. Furthermore, the compound nutrients can also be formulated in-house. The term "compound" is used in this invention for ease of description only and does not imply that the components in the compound must be mixed together before application. All raw materials should be added and used in compliance with relevant regulations.

[0043] According to some specific embodiments of the present invention, the infant or child formula of the present invention enhances an individual's memory ability in adulthood through early intervention, thereby achieving memory assistance and improvement. Specifically, enhancing and / or improving an individual's memory ability in adulthood includes: Enhance and / or improve an individual's object recognition and memory abilities in adulthood; Enhance and / or improve an individual's spatial memory and pattern separation abilities in adulthood; To enhance and / or improve an individual's learning and memory abilities in adulthood; and / or Increase the number of hippocampal neurons in adults.

[0044] On the other hand, the present invention also provides a method for preparing the infant or child formula food.

[0045] In some specific embodiments of the present invention, the infant or child formula food is in powder form, and the method includes: Ingredient preparation, homogenization, concentration and sterilization, spray drying, dry mixing, and preparation of the finished product; Human milk oligosaccharides are added during the ingredient preparation process.

[0046] In some specific embodiments of the present invention, the method for preparing powdered infant or child formula includes: Milk coarse filtration: After coarse filtration and degassing in the balance tank, the milk is preheated by a plate heat exchanger and then separated by a separator to remove impurities. Milk homogenization and sterilization: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and put into the sterilization system for sterilization. Powder addition: Various powder raw materials, including human milk oligosaccharides, are metered according to the formula and then added to the powder mixing tank through the pneumatic conveying system for storage. Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through a vacuum system; Melting and blending oil: The oils specified in the formula are placed in the melting room according to the formula requirements. After the oils are melted, they are pumped into the mixed oil storage tank through an oil pump and a flow meter according to the formula ratio. Mixed oil storage: The mixed oil is stored in an insulated oil storage tank; Weighing: The mixed oil is pumped into the mixing tank according to the formula requirements; Nutrient dissolution and addition: Calcium powder, minerals, vitamins, etc. are added separately, dissolved in purified water, and then added to the wet mixing tank; Filtration: The mixed liquid is filtered through a filter screen to remove any physical impurities that may have been introduced from the raw materials; Homogenization: The mixed liquid is homogenized by a homogenizer to mechanically disperse the fat globules into uniform fat globules; Cooling and storage: The homogenized liquid enters a plate heat exchanger for cooling and is temporarily stored in a pre-storage tank; Concentration and sterilization: Double-effect concentration and sterilization are used during production; the output concentration is 48%-52% dry matter concentrated milk. Concentrated milk storage, preheating filtration, and spray drying: The concentrated milk is temporarily stored in a concentrated milk balance tank; after preheating by a scraper preheater, it is filtered and then sprayed into a drying tower by a high-pressure pump. Fine powder is agglomerated at the top of the tower or in a fluidized bed as required; inlet air temperature: 165-180℃, exhaust air temperature: 75-90℃, high-pressure pump pressure: 160-210 bar, tower negative pressure: -4 to -2 mbar. Fluidized bed drying and cooling: The powder from the drying tower is dried again in a fluidized bed and then cooled in a fluidized bed; at the same time, the phospholipid is mixed with the carrier and heated, and then evenly dispersed on the powder surface under the action of compressed air, so that the powder particles agglomerate, increasing their particle size and solubility; Dry mixing: As needed, the pre-packaged and weighed dry mixing ingredients are mixed with milk powder in a dry mixing machine; then, after sieving and packaging, the infant or child formula food product is prepared.

[0047] All references to "infants" or "children" in this document should ensure that the technology, products, or methods of this invention comply with safety standards and suitability for use by infants or children. The design and usage parameters of specific products or devices may be appropriately adjusted according to the characteristics of different age groups to ensure their safety and effectiveness.

[0048] The infant or child formula of the present invention improves memory by intervening in early life (especially infancy) to enhance an individual's memory ability in adulthood. Attached Figure Description

[0049] Figure 1 The results show the new object recognition memory outcomes in rats supplemented with 2'-FL during juvenile years.

[0050] Figure 2 The results of novel location recognition memory in rats supplemented with 2'-FL during juvenile stage (easy condition).

[0051] Figure 3 The results show the new object recognition memory outcomes in rats supplemented with 3'-SL and / or 6'-SL during juvenile stage.

[0052] Figure 4 The results of novel location recognition memory in rats supplemented with 3'-SL and / or 6'-SL during juvenile period (easy condition).

[0053] Figure 5 The results of novel location recognition memory (difficult mode) in rats supplemented with 3'-SL and / or 6'-SL during juvenile period are shown.

[0054] Figure 6 This shows the results of novel object recognition and memory in rats supplemented with HMO monomers and compositions during juvenile stage.

[0055] Figure 7 This shows the results of novel location recognition memory in rats supplemented with HMO during juvenile stage (easy mode).

[0056] Figure 8 This shows the results of novel location recognition memory (difficult mode) in rats supplemented with HMO during juvenile period.

[0057] Figure 9 The results of staining show the number of newly generated neurons in the hippocampus of rats supplemented with HMO in their early years. Detailed Implementation

[0058] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention.

[0059] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, the two endpoints of each numerical range and any value between the two endpoints may be selected.

[0060] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art.

[0061] As used herein, the term "enhanced memory" means an improvement in an individual's memory capacity (including short-term memory, long-term memory, memory recall, and / or memory recognition, etc.) compared to the same response in the absence of the human milk oligosaccharides of this invention. This includes, but is not limited to, enhanced object recognition memory, enhanced spatial and pattern separation memory, enhanced learning memory, and increased hippocampal neuron count. In relation to any beneficial effects on memory capacity, the term "enhanced" is synonymous with "strengthened," "improved," or "promoted." In some embodiments of the present invention, particularly in cases where an individual's memory capacity is impaired, declining, or threatened, the term "improving memory capacity" refers to actions that reduce, mitigate, or alleviate the degree of memory impairment or decline, or reduce the risk of memory impairment or decline, including but not limited to: alleviating adverse symptoms associated with memory impairment or decline; slowing or preventing the onset of symptoms before they occur; slowing or halting the progression of memory impairment or decline; slowing or halting the worsening of memory impairment or decline; slowing or halting irreversible damage in the progressive (or chronic) phase of memory impairment or decline; delaying the onset of (progressive) memory impairment or decline; reducing the severity of memory impairment or decline; curing memory impairment or decline; and preventing the occurrence of memory impairment or decline. As used herein, the term "memory impairment" refers to impaired, diminished, or declining learning, memory, and / or cognitive functions, to the point that normal functioning is difficult to maintain or achieve without intervention. Some common signs of memory decline include confusion, short-term or long-term memory loss, and decreased object recognition and / or spatial judgment.

[0062] As used herein, the term “individual” means any animal or human who may benefit from the memory-enhancing products of this invention.

[0063] Unless otherwise specified, the term "infant or child" as used in this instruction manual refers to a person aged 0 to 15 years. Based on different age groups and developmental characteristics, "infant or child" can be further divided into infants, toddlers, or children. The term "infant" refers to a human being aged 0-3 years from birth. Infancy (0-1 year): refers to children from birth to one year of age. Early childhood (1-3 years): refers to children aged 1 to 3 years. The term "child" refers to a human being aged 3-15 years from birth.

[0064] In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of those skilled in the art and the description of this invention, any prior art methods, equipment, and materials similar to or equivalent to those described, equipment, and materials in the embodiments of this invention can be used to implement this invention.

[0065] Unless otherwise stated, the experimental methods, detection methods and preparation methods disclosed in this invention all adopt conventional techniques in this technical field.

[0066] In all embodiments and experiments, all human milk oligosaccharides used were commercially available food-grade raw materials. Unless otherwise specified, the amount of human milk oligosaccharides mentioned in this invention is based on the effective content.

[0067] Example 1

[0068] This embodiment provides a powdered infant formula food, which has a total protein content of 11.4g / 100g powder, a fat content of 26.1g / 100g powder, a carbohydrate content of 53.5g / 100g powder, and a 2'-FL content of 1000mg / 100g.

[0069] This embodiment is achieved by compounding the following raw materials in parts by weight, and the raw material composition includes (for preparation of 1000 parts by weight): 1500 parts raw milk, 515 parts demineralized whey powder (D90), 198 parts blended edible vegetable oil, 68 parts galactooligosaccharides, 4 parts fructooligosaccharides, 4 parts phospholipids, and 28 parts compound nutrients, including approximately 4 parts compound vitamin nutrient packs, approximately 2 parts choline chloride nutrient packs, approximately 19 parts mineral II nutrient packs, approximately 1 part mineral I nutrient pack, and approximately 2 parts magnesium chloride nutrient packs. The base of each nutrient pack is lactose, 11 parts DHA, 15 parts ARA, approximately 0.7 parts nucleotides, 2 parts lactoferrin, and 13 parts 2'-FL.

[0070] The specific preparation process of the infant formula milk powder in this embodiment is as follows: 1) Coarse filtration of milk: After coarse filtration and degassing in a balance cylinder, the milk is preheated by a plate heat exchanger and then separated by a separator to remove impurities. 2) Homogenization and sterilization of milk: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and put into the sterilization system for sterilization. 3) Powder addition: Various powder raw materials are metered according to the formula and added to the powder mixing tank through the pneumatic conveying system, and then sucked into the vacuum mixing tank through the vacuum system; 4) Melting and blending oil: According to the formula requirements, put the oil specified in the formula into the melting room. The temperature of the melting room is maintained at 50~90℃. After the oil is melted, pump it into the mixed oil storage tank, and pump the mixed oil into the mixing tank through the oil pump according to the formula requirements. 5) Nutrient dissolution and addition: Dissolve the calcium powder, vitamins, minerals and other nutrient packets separately in purified water, and then add them to the mixing tank in sequence to obtain a mixed liquid. 6) Filtration: The mixed liquid is filtered through a filter screen to remove any physical impurities that may have been introduced from the raw materials; 7) Homogenization: The mixed liquid is homogenized by a homogenizer to mechanically process the fat globules and disperse them into uniform fat globules; 8) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It will enter the next process within 6 hours, and the agitator will be turned on as required. 9) Concentration and Sterilization: Double-effect concentration is used during production, with a sterilization temperature ≥83℃ and a sterilization time of 25 seconds. The output concentration is 50% dry matter. 10) Concentrated milk storage, preheating and filtration, and spray drying: The concentrated milk is temporarily stored in a concentrated milk balance tank. It is preheated to 60℃ by a scraper preheater. After preheating, the material is filtered through a 1mm pore size filter and then spray-dried in a drying tower using a high-pressure pump. Fine powder agglomerates at the top of the tower or in a fluidized bed as required. Inlet air temperature: 180℃, exhaust air temperature: 86℃, high-pressure pump pressure: 200 bar, tower negative pressure: approximately -4 mba. 11) Fluidized bed drying and cooling: The powder from the drying tower is dried again in a fluidized bed (primary stage) and then cooled to 30°C in a fluidized bed (secondary stage) to obtain the main milk powder material; 12) Packaging: Weigh and seal the DHA, ARA, lactoferrin or bifidobacteria according to the formula requirements; 13) Dry mixing: Mix the weighed DHA, ARA, lactoferrin or bifidobacteria with the main ingredients of milk powder in a dry mixer. 14) Sieving: The milk powder is sieved to make the particle size uniform, and the powder residue is disposed of as waste. 15) Powder discharge: Collect the powder in a sterilized powder collection box and transport it from the powder discharge room to the powder loading room; 16) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements; 17) Packaging: 400g automatic packaging machine with nitrogen filling. Oxygen content is less than 1% during nitrogen filling. 900g iron cans are automatically packaged with nitrogen filling, with oxygen content less than 5%. 18) Packing: Place the packaged small bags into the cardboard box along with the powder scoop, and seal the box with a carton sealing machine; 19) Finished product inspection: Sampling inspection of packaged products according to the inspection plan; 20) Warehousing and storage: Products that have passed inspection shall be stored in the warehouse at room temperature with a humidity of ≤65%.

[0071] Example 2

[0072] This embodiment provides a powdered infant formula for toddlers. The powdered formula contains 14.5g of total protein per 100g of powder, 21.3g of fat per 100g of powder, 54g of carbohydrates per 100g of powder, 80mg of 3'-SL per 100g of powder, and 283mg of 6'-SL per 100g of powder. The mass ratio of 3'-SL to 6'-SL is 1:3.5.

[0073] This embodiment is achieved by compounding the following raw materials in parts by weight, and the raw material composition includes (for preparation of 1000 parts by weight): 2600 parts raw milk, 400 parts demineralized whey powder (D90), 112 parts blended edible vegetable oil, 40 parts skim milk powder, 15 parts lactose, 68 parts galactooligosaccharides, 5 parts fructooligosaccharides, 4 parts phospholipids, and 25 parts compound nutrients, including approximately 4 parts compound vitamin nutrient packs, approximately 3 parts choline chloride nutrient packs, approximately 15 parts mineral II nutrient packs, approximately 2 parts mineral I nutrient packs, and approximately 1 part magnesium chloride nutrient pack. The base of each nutrient pack is lactose, 10 parts DHA, 15 parts ARA, approximately 0.7 parts nucleotides, 2 parts lactoferrin, 1.2 parts 3'-SL, and 4 parts 6'-SL.

[0074] The specific preparation process of the infant formula in this embodiment is the same as that in Example 1.

[0075] Example 3

[0076] This embodiment provides a powdered infant formula food, which has a total protein content of 21.0g / 100g powder, a fat content of 13g / 100g powder, a carbohydrate content of 59g / 100g powder, a 2'-FL content of 543mg / 100g, a 3'-SL content of 198mg / 100g, and a 6'-SL content of 230mg / 100g. The mass ratio of 2'-FL, 3'-SL, and 6'-SL is 3:1:1.2.

[0077] This embodiment is achieved by compounding the following raw materials in parts by weight, and the raw material composition includes (for preparation of 1000 parts by weight): 3300 parts raw goat milk, 320 parts skim milk powder, 260 parts lactose, 2 parts phospholipids, and 20 parts compound nutrients. The compound nutrients include approximately 3 parts compound vitamin nutrient pack, approximately 1 part choline chloride nutrient pack, approximately 15 parts mineral II nutrient pack, and approximately 1 part mineral I nutrient pack. The base ingredients of each nutrient pack are lactose, DHA 5 parts, ARA 4 parts, Bifidobacterium 0.2 parts, lactoferrin 1 part, 2'-FL 7 parts, 3'-SL 2.9 parts, and 6'-SL 3.4 parts.

[0078] The specific preparation process of the children's formula food in this embodiment is the same as that in Example 1.

[0079] Example 4: An experiment on the improvement of adult memory through early intervention with formulated foods.

[0080] 1. Animal models

[0081] The Long Evans rat breeding pairs used in this experiment were purchased from Envigo, USA, for internal breeding of the rats required for the experiment. To ensure that the mother rats could provide adequate care for each pup, litters with more than 10 pups were artificially adjusted to fewer than 10 pups within the first 0 to 1 day after birth. The pups were weaned on day 21 after birth. The rats were housed in an environment with reversed diurnal cycles, i.e., 12 hours of darkness and 12 hours of light (lights off at 9:00 AM and on at 9:00 PM), to adapt to the rats' active cycles.

[0082] 2. HMO intervention

[0083] This study included three different human lactose oligosaccharides (HMOs): 2'-fucosylated lactose (2'-FL), 3'-sialyl lactose (3'-SL), and 6'-sialyl lactose (6'-SL), alone or in combinations of two or three. These HMOs were administered as individual HMOs or in different combinations to juvenile rats (from day 8 to day 35 after birth), forming different group settings with 27 rats in each group. The control group received no HMOs but was given plain drinking water in the same manner as other animals receiving HMOs. The HMOs, either individual or combined, were administered orally by gavage at a daily dose of 400 mg / kg body weight.

[0084] 3. Behavioral research

[0085] After the intervention period ended, all rats in each group were housed in a uniform environment with reversed day and night cycles, fed standard rat diet (without HMOs), and allowed free access to food.

[0086] Rats were assessed behaviorally using memory tests during weeks 32-34, as detailed below: The Novel Object Recognition Test (NORT) is a behavioral task used to assess recognition memory. It measures the time an animal takes to explore a newly introduced object after becoming familiar with a pair of identical objects. In this task, two identical objects are initially presented in a test box, and in the retest phase, one of the objects is replaced with a new object. The time an animal spends exploring the replaced object reflects its object recognition memory ability. NORT is based on an animal's preference for exploring new objects. In the experiment, animals typically spend more time exploring new objects than familiar ones. This preference reflects the animal's ability to recognize and remember new objects.

[0087] In addition to novel object recognition, this experimental study also included a novel object location task (NOLT) to measure the animals' learning and memory abilities. The NOLT utilizes the rats' natural curiosity: when an animal recognizes an object has been moved, it is more inclined to explore the moved object. The variation in the time taken to explore the object at different possible locations was used as a measure of pattern separation. NOLT is a behavioral task used to measure spatial memory and pattern separation (van Goethem, van Hagen & Prickaerts, 2018). The time an animal takes to explore a moved object reflects its spatial memory and pattern separation abilities. The object locations were labeled P1 (location 1), P3 (location 3), and P5 (location 5). Larger numbers indicate greater displacement of the object from the center of the test box, with P1 being the intermediate location (the same as the object location in the acquisition phase). The NOLT study used in this project included two experimental conditions: 1) Easy condition (location 5, P5): In the easy condition, the object was displaced a greater distance from its original location during the test phase. This is considered a low-mode separation condition because displacement of an object over a larger distance is considered easier for the animal to detect; 2) Difficult condition (position 3, P3): Under this condition, the object is displaced a small distance from its original position during the testing phase. This is considered a high-mode separation condition because small-distance displacements are considered harder for the animal to detect.

[0088] 4. Fluorescent staining experiment

[0089] After behavioral studies confirmed that the HMO composition had activity promoting adult cognitive development, the effects of the HMO composition on the rat brain were further investigated. The number of newly generated neurons in the hippocampus was determined using a 5-bromodeoxyuridine staining assay. 5-bromodeoxyuridine is an analog of thymine nucleoside, which can be incorporated into newly synthesized DNA during the DNA synthesis phase of the cell cycle and is commonly used to detect proliferating cells. Female rats in the HMO intervention group underwent staining experiments 3 days before sacrifice. Rats received intraperitoneal (IP) injections of 5-bromodeoxyuridine at the same time for 3 consecutive days at a dose of 100 mg / kg body weight to ensure consistent labeling of newly generated neurons. Brain samples were collected after rat sacrifice, and hippocampal sections were stained. 5-bromodeoxyuridine-positive cells were manually counted using Cell-Counter in ImageJ.

[0090] 5. Statistical Analysis

[0091] The study used IBM SPSS software version 20.0 for data analysis. A difference was considered statistically significant when the reported p-value was less than 0.05, and statistical trend was defined as a p-value less than or equal to 0.1.

[0092] Early intervention with 2'-FL improves adult memory

[0093] In this embodiment, following the aforementioned experimental protocol for "Early Intervention of Test Substances to Improve Adult Memory," the effects of early intervention with 2'-fucolactose (2'-FL) on the learning and memory abilities of adult rats were tested. 2'-FL was administered as a single HMO to juvenile rats (from day 8 to day 35 after birth), resulting in the following group setup: a control group (receiving drinking water) and a 2'-FL intervention group. The control group did not contain any HMOs but was given ordinary drinking water in the same manner as other animals receiving HMOs. Each group consisted of 27 rats. 2'-FL was administered orally by gavage at a dose of 400 mg / kg body weight daily.

[0094] Figure 1 This study shows the results of novel object recognition memory in rats supplemented with 2'-FL during juvenile stage. The NORT experiment was conducted at weeks 32-34 of rat life, and data are expressed as the mean and standard error of the discrimination index. The results showed that the novel object discrimination index was increased in the 2'-FL intervention group compared to the control group. This indicates that 2'-FL intervention during juvenile stage has a significant effect on improving memory abilities in adulthood.

[0095] Figure 2 This study shows the results of novel location recognition and memory in rats supplemented with 2'-FL during juvenile stage (easy mode). The NOLT experiment was conducted at weeks 32-34 of rat life, and data are expressed as the mean and standard error of the number of times the experimental animals correctly identified and explored objects in novel locations during the test phase. The results showed that the 2'-FL intervention group had a higher number of correct answers compared to the control group. This indicates that 2'-FL intervention during juvenile stage has a significant effect on improving learning and memory abilities in adulthood.

[0096] Early intervention with 3'-SL and / or 6'-SL improves adult memory.

[0097] In this embodiment, following the aforementioned experimental protocol for "Early Intervention of Test Substances to Improve Adult Memory," the effects of early intervention with 3'-sialactose (3'-SL) and / or 6'-sialactose (6'-SL) on learning and memory abilities in adult rats were tested. These HMOs were administered as single HMOs or in combination during juvenile rats (from day 8 to day 35 after birth), forming the following groups: control group (receiving drinking water), HMO single group, and HMO combination group (3'-SL + 6'-SL, with a mass ratio of 3'-SL to 6'-SL of 1:2). The control group received no HMOs but was given ordinary drinking water in the same manner as other animals receiving HMOs; each group consisted of 27 rats. The HMO single group or combination group was administered 400 mg / kg body weight orally via gavage daily (i.e., the HMO combination group was administered 133 mg / kg body weight of 3'-SL + 267 mg / kg body weight of 6'-SL orally via gavage daily).

[0098] Figure 3 This study demonstrates the results of novel object recognition and memory in rats supplemented with 3'-SL and / or 6'-SL during juvenile stage. The NORT experiment was conducted at weeks 32-34 of rat life, and data are expressed as mean and standard error of the discrimination index. Results showed that the novel object discrimination index was increased in the sialic acid intervention group compared to the control group. In particular, the 3'-SL+6'-SL combination group had the highest object recognition index, indicating that sialic acid intervention during juvenile stage significantly improves memory ability in adulthood, and that the two sialic acid oligosaccharides have a synergistic effect.

[0099] Figure 4 The results show the novel location recognition memory outcomes (easy condition) of rats supplemented with 3'-SL and / or 6'-SL during juvenile stage. The NOLT experiment was conducted at weeks 32-34 of rat life, and data are expressed as the mean and standard error of the number of correct answers. The results showed that, compared with the control group, the 6'-SL group and the 3'-SL+6'-SL intervention group had increased novel location discrimination indices. This indicates that sialic acid oligosaccharide intervention during juvenile stage, especially 6'-SL and the combination of 3'-SL and 6'-SL, has a significant effect on improving learning and memory abilities in adulthood.

[0100] Figure 5The results show the novel location recognition and memory outcomes (difficult mode) of rats supplemented with 3'-SL and / or 6'-SL during juvenile stage. The closer the novel location is to the center, the greater the recognition difficulty. Therefore, the performance of rats in the difficult mode can indicate their performance in handling complex tasks. The experimental results showed that, compared with the control group, the novel location discrimination index was increased in the 6'-SL group and the 3'-SL+6'-SL intervention group. This indicates that sialic acid oligosaccharide intervention during juvenile stage, especially 6'-SL and the combination of 3'-SL and 6'-SL, has a significant effect on improving learning and memory abilities in adulthood.

[0101] Early intervention with HMOs improves adult memory.

[0102] In this embodiment, following the aforementioned "Experimental Protocol for Early Intervention of Test Substances to Improve Adult Memory," three different human lactose oligosaccharides (HMOs) were tested: 2'-fucosylated lactose (2'-FL), 3'-sialyl lactose (3'-SL), and 6'-sialyl lactose (6'-SL). These HMOs were administered as individual HMOs or in different combinations to juvenile rats (from day 8 to day 35 after birth), forming the following groups: control group (receiving drinking water), HMO monomer groups (2'-FL, 3'-SL, and 6'-SL groups), HMO composition 1, HMO composition 2, and HMO composition 3. Each control and HMO monomer group consisted of 27 rats, and each HMO combination group consisted of 27 rats. The control group received no HMOs but was given ordinary drinking water in the same manner as other animals receiving HMOs. The daily dose of either the HMO monomer or the combination administered orally via gavage was 400 mg / kg body weight (the gavage dose for the HMO combination group was the total HMO dose of 400 mg / kg body weight).

[0103] The experimental group information is shown in Table 1.

[0104] Table 1. Experimental group settings

[0105] Figure 6 This study shows the results of novel object recognition and memory in rats supplemented with HMOs during juvenile stage. The NORT experiment was conducted at 32-34 weeks of rat life, and data are expressed as the mean and standard error of the discrimination index. The results showed that the novel object discrimination index was increased in the HMO combination intervention groups compared to the control group. In particular, HMO combination 1 group had the highest object recognition index, followed by HMO combination 3 group and the 6'-SL group, indicating that intervention with human milk oligosaccharides during juvenile stage significantly improves memory ability in adulthood, and the three HMO combinations showed a certain synergistic effect.

[0106] Figure 7The results show the novel location recognition memory outcomes (easy mode) of rats supplemented with HMOs during juvenile stage. The NOLT experiment was conducted at 32-34 weeks of age, and data are expressed as the mean and standard error of the number of correct answers. The results showed that the novel location discrimination index was increased in HMO combination 1 and HMO combination 3 groups compared with the control group. This indicates that intervention with human milk oligosaccharides during juvenile stage, especially the combination of 2'-FL, 3'-SL, and 6'-SL, has a significant effect on improving learning and memory abilities in adulthood.

[0107] Figure 8 The results show the novel location recognition and memory outcomes (difficult mode) of rats supplemented with HMOs during juvenile stage. The closer the novel location is to the center, the greater the recognition difficulty. Therefore, the performance of rats in the difficult mode can indicate their performance in handling complex tasks. In this experiment, no meaningful statistical data were obtained for the 2'-FL group and the HMO composition 3 group due to operational abnormalities, and they are not shown in the figure. The experimental results show that, compared with the control group, the novel location discrimination index of the HMO composition 1 group and the HMO composition 2 group intervention group was increased. This indicates that HMO composition intervention during juvenile stage, especially the combination of 2'-FL, 3'-SL, and 6'-SL, has a significant effect on improving learning and memory abilities in adulthood, especially the ability to handle complex situations.

[0108] After behavioral experiments confirmed the positive impact of early intervention with HMO combinations on cognitive development in adulthood, the number of newly generated neurons in the brains of rats in the HMO combination groups was measured. Fluorescent staining was used to analyze the differences in newly generated neurons in the brains of rats in the control group and the HMO combination groups 1, 2, and 3. Figure 9 The results show the staining results of the number of newly generated neurons in the hippocampus of rats supplemented with HMOs during childhood. The results indicate that, compared with the control group, the intervention groups (HMO composition 1 and HMO composition 3) had an increased number of fluorescently positive cells, indicating an increase in the number of newly generated neurons in the hippocampus. This suggests that intervention with HMO compositions during childhood, especially the combinations of 2'-FL, 3'-SL, and 6'-SL, may enhance cognitive development in adulthood by increasing the number of newly generated neurons in the hippocampus.

[0109] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. Use of human milk oligosaccharides as an active ingredient in the preparation of infant or child formula foods that help enhance and / or improve an individual's memory abilities in adulthood; in, Based on the dry matter content of the infant or child formula, the total protein content is 10g-30g / 100g, the fat content is 10g-35g / 100g, the carbohydrate content is 45g-65g / 100g, and the dietary fiber content is 0-6.5g / 100g. The human milk oligosaccharide is selected from one or more of 2'-fucosylated lactose (2'-FL), 3'-sialylated lactose (3'-SL), and 6'-sialylated lactose (6'-SL); The product is an oral product intended for use by minors.

2. The use according to claim 1, wherein, Human milk oligosaccharides are: 2'-Fucose-based lactose; 3'-Sialolactose; 6'-Sialolactose; A combination of 3'-sialyl lactose and 6'-sialyl lactose; or A combination of 2'-fucosylated lactose, 3'-sialylated lactose, and 6'-sialylated lactose; Optionally, in the combination of 3'-sialyl lactose and 6'-sialyl lactose, the mass ratio of 3'-sialyl lactose to 6'-sialyl lactose is 1:(1-4), preferably 1:(1.5-2.5) or 1:(2-3). Optionally, in the combination of 2'-fucosylated lactose, 3'-sialylated lactose and 6'-sialylated lactose, the mass ratio of 2'-fucosylated lactose, 3'-sialylated lactose and 6'-sialylated lactose is (1-12):1:(1-4), preferably (1-12):1:(2-3) or (1-12):1:(1.5-2.5), and more preferably (4-10):1:(2-3).

3. The use according to claim 1 or 2, wherein, The total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL, based on the dry matter of the infant or child formula, is 10-6000 mg / 100g of dry matter. Optionally, the total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL in the infant or child formula is 10-4000 mg / 100g dry matter. Optionally, the total content of human milk oligosaccharides 2'-FL, 3'-SL and 6'-SL in the infant or child formula is 20-2387 mg / 100g of dry matter.

4. The use according to any one of claims 1-3, wherein, The infant or child formula foods include, but are not limited to: powdered infant formula foods, liquid infant formula foods, powdered modified infant milk powder, infant formula foods for special medical purposes, cheese, and milk tablets; wherein, the powdered infant formula foods include powdered infant formula foods, powdered follow-up formula foods, or powdered toddler formula foods, and the liquid infant formula foods include liquid infant formula foods, liquid follow-up formula foods, or liquid toddler formula foods.

5. The use according to claim 4, wherein, Based on the preparation of 1000 parts by weight of the powdered infant formula, the raw material composition of the powdered infant formula includes: 0-7000 parts by weight of raw milk, 0-600 parts by weight of demineralized whey powder, 0-500 parts by weight of lactose, 0-600 parts by weight of skim milk powder, 0-400 parts by weight of edible vegetable blended oil, 0-250 parts by weight of dietary fiber, 0-170 parts by weight of whey protein powder, 0-20 parts by weight of phospholipids, 0-20 parts by weight of vitamins, 0-40 parts by weight of casein, and 0-30 parts by weight of minerals. To prepare 1000 parts by weight of the aforementioned infant formula liquid milk, the raw material composition of the infant formula liquid milk includes: 0-930 parts by weight of water, 0-950 parts by weight of raw milk, 0-75 parts by weight of skim milk powder, 0-75 parts by weight of demineralized whey powder, 0-75 parts by weight of lactose, 0-60 parts by weight of edible vegetable blended oil, 0-35 parts by weight of dietary fiber, 0-18 parts by weight of whey protein powder, 0-2 parts by weight of phospholipids, 0-6 parts by weight of casein, 0-3 parts by weight of vitamins, and 0-5 parts by weight of minerals; Based on the preparation of 1000 parts by weight of the powdered infant formula milk powder, the raw material composition of the powdered infant formula milk powder includes 0-7000 parts by weight of raw milk, 0-500 parts by weight of skim milk powder, 0-300 parts by weight of demineralized whey powder, 0-170 parts by weight of whey protein powder, 0-500 parts by weight of lactose, 0-250 parts by weight of dietary fiber, 0-5 parts by weight of choline, 0-10 parts by weight of phospholipids, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals.

6. The use according to any one of claims 1-5, wherein, The ingredients of the infant or child formula include: 0-5200 parts by weight of raw milk; Lactose 0-330 parts by weight; Whole milk powder 0-300 parts by weight; Skim milk powder 0-500 parts by weight; Demineralized whey powder 0-580 parts by weight; Desalted whey solution, 0-4000 parts by weight; Skim milk 0-4000 parts by weight; Whey protein powder 0-170 parts by weight; 0-350 parts by weight of whey protein solution; Blended oil 0-280 parts by weight; Sunflower seed oil 0-110 parts by weight; Corn oil 0-40 parts by weight; Soybean oil 0-80 parts by weight; Coconut oil 0-30 parts by weight; Low-erucic acid rapeseed oil, 0-85 parts by weight; 0-20 parts by weight of flaxseed oil; 0-240 parts by weight of 1,3-dioleoyl-2-palmitoylglycerol triglyceride; α-lactalbumin powder 0-55 parts by weight; Whey protein powder (rich in milk fat globule membrane) 0-50 parts by weight; 0-40 parts by weight of β-casein powder; 0-5 parts by weight of soybean lecithin; 0-2 parts by weight of anhydrous butter; 0-50 parts by weight of fructooligosaccharide powder; 0-100 parts by weight of galactooligosaccharide syrup; A complex of nutrients containing calcium powder, vitamins and minerals, 4.5-37.5 servings by weight; DHA 0-20 parts by weight; ARA 0-25 parts by weight; Lactoferrin 0-8.5 parts by weight; 0-1 parts by weight of nucleotides; Probiotics 0-10 parts by weight.

7. The use according to claim 1, wherein, Enhancing and / or improving an individual's memory abilities in adulthood includes: Enhance and / or improve an individual's object recognition and memory abilities in adulthood; Enhance and / or improve an individual's spatial memory and pattern separation abilities in adulthood; To enhance and / or improve an individual's learning and memory abilities in adulthood; and / or Increase the number of hippocampal neurons in adults.

8. An infant or child formula that helps to enhance and / or improve an individual's memory ability in adulthood, wherein, based on the dry matter content of the infant or child formula, the total protein content is 10g-30g / 100g, the fat content is 10g-35g / 100g, the carbohydrate content is 45g-65g / 100g, and the dietary fiber content is 0-6.5g / 100g; in, The human milk oligosaccharide is selected from one or more of 2'-fucosylated lactose (2'-FL), 3'-sialylated lactose (3'-SL), and 6'-sialylated lactose (6'-SL); Optionally, the infant or child formula is the infant or child formula as described in any one of claims 1-7.

9. The method for preparing infant or child formula food according to claim 8, wherein, The infant or child formula food is in powder or liquid form; Methods for preparing powdered food include: ingredient mixing, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain the finished product; Methods for preparing liquid foods include: ingredient preparation, homogenization, sterilization, and filling, to obtain the finished product; Human milk oligosaccharides are added during the ingredient preparation process.

10. The preparation method according to claim 9, wherein the method is for preparing powdered food, the method comprising: Milk coarse filtration: After coarse filtration and degassing in the balance tank, the milk is preheated by a plate heat exchanger and then separated by a separator to remove impurities. Milk homogenization and sterilization: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and put into the sterilization system for sterilization. Powder addition: Various powder raw materials, including human milk oligosaccharides, are metered according to the formula and then added to the powder mixing tank through the pneumatic conveying system for storage. Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through a vacuum system; Melting and blending oil: The oils specified in the formula are placed in the melting room according to the formula requirements. After the oils are melted, they are pumped into the mixed oil storage tank through an oil pump and a flow meter according to the formula ratio. Mixed oil storage: The mixed oil is stored in an insulated oil storage tank; Weighing: The mixed oil is pumped into the mixing tank according to the formula requirements; Nutrient dissolution and addition: Calcium powder, minerals, vitamins, etc. are added separately, dissolved in purified water, and then added to the wet mixing tank; Filtration: The mixed liquid is filtered through a filter screen to remove any physical impurities that may have been introduced from the raw materials; Homogenization: The mixed liquid is homogenized by a homogenizer to mechanically disperse the fat globules into uniform fat globules; Cooling and storage: The homogenized liquid enters a plate heat exchanger for cooling and is temporarily stored in a pre-storage tank; Concentration and sterilization: Double-effect concentration and sterilization are used during production; the output concentration is 48%-52% dry matter concentrated milk. Concentrated milk storage, preheating filtration, and spray drying: The concentrated milk is temporarily stored in a concentrated milk balance tank; after preheating by a scraper preheater, it is filtered and then sprayed into a drying tower by a high-pressure pump. Fine powder is agglomerated at the top of the tower or in a fluidized bed as required; inlet air temperature: 165-180℃, exhaust air temperature: 75-90℃, high-pressure pump pressure: 160-210 bar, tower negative pressure: -4 to -2 mbar. Fluidized bed drying and cooling: The powder from the drying tower is dried again in a fluidized bed and then cooled in a fluidized bed; at the same time, the phospholipid is mixed with the carrier and heated, and then evenly dispersed on the powder surface under the action of compressed air, so that the powder particles agglomerate, increasing their particle size and solubility; Dry mixing: As needed, the pre-packaged and weighed dry mixing ingredients are mixed with milk powder in a dry mixing machine; then, after sieving and packaging, the infant or child formula food product is prepared.

Images